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ABSTRACT 
The discovery and development of effective chemotherapeutic agents in the past few decades 
have immensely enhanced the treatment and management of human cancer. However, because 
these drugs are associated with adverse side effects, high genotoxicity, risk for secondary cancers 
and devastating effects on the patients’ immune system; the need for developing more effective 
anticancer agents remains. A priority Research shows that 9-aminoacridine (9AA) derivatives 
have substantial anticancer properties. The pharmacological properties of this agent are well 
characterized and this scaffold has been widely used to treat different diseases for decades. 
Quinacrine is a 9AA derivative, which was first discovered as an antimalarial compound in 
1930’s and since then had been widely used in treating a variety of parasitic infections and 
demonstrated potential for cancer treatment. Importantly, the polypharmacology of Quinacrine 
makes it an attractive drug to treat a variety of cancers. Quinacrine acts by specifically targeting 
cellular signaling pathways that play an important role in cell survival. Given the distinctive 
cancer treating abilities of Quinacrine by specifically targeting cellular signaling pathways, it 
was the objective of this study to develop a compound that has similar properties as Quinacrine 
but has better efficacy and selectivity in targeting tumor cells. Therefore, for this project we 
created derivatives of 9AA compound using hybrid pharmapore approach and examined one of 
the derivatives of Quinacrine compound named VR118. After performing a series of experiments 
to test the efficacy and selectivity of the Quinacrine derivative VR118, I came to the conclusion 
that VR118 is highly effective in treating cancer cells and have the potential to selectively target 
cancer cells without causing severe harm to normal cells at concentrations applicable for 
malignant cell lines. This report discusses the efficacy and selectivity of VR118 compound in 
targeting cellular signaling pathways and the mechanisms through which VR118 kills cancer 
cells. 
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Chapter 1 
1 INTRODUCTION 
1.1 Cancer Epidemiology 
Cancer is an extremely heterogeneous disease that occurs due to series of genetic changes and 
molecular events that fundamentally alter the normal properties of cells. Therefore, cancer is a 
generic term that is generally used to describe a large group of malignant tumors and neoplasms 
affecting any part of the body (Does et al., 2013). Normal cells in a multicellular organism 
function in accordance with the normal rules that govern the basic function of cells such as cell 
growth, reproduction, and apoptosis (programmed cell death) (Does et al., 2013). However, 
cancer cells do not function normally and, therefore, proliferate despite the presence of signals 
that normally inhibit cell growth and proliferation. 
Many intracellular changes can cause cells to develop new characteristics; such as changes in 
cell structure, cell adhesion, and the production of new enzymes that lead to the loss of contact 
inhibition, loss of the apoptotic pathway, failure to mature and differentiate, and finally 
developing the ability to metastasize (Schneider, 2001). Metastasis is a critical step in the 
progression of cancer and is a major cause of death in cancer patients. When malignant cancer 
cells invade other tissues and organs, they may alter the cellular signaling pathways within these 
cells. This leads to the loss of function and efficiency of cellular signaling pathways that are 
required to control particular functions within these cells. Given the complex changes in cell 
behavior of metastatic cells along with the unpredictable nature of cancer cells in tissues where 
they invade, cells’ response to a cancer therapy varies from patient to patient and case-by-case 
depending on the site and organ affected (Schneider, 2001). 
Despite advances in treatment modalities in recent decades, cancer still remains largely a fatal 
disease. Globally, cancer was the leading cause of death in 2008 accounting for 7.6 million 
deaths (Globocan, 2008). The World Health Organization (WHO) estimates that cancer will 
account for approximately 13.1 million deaths worldwide by 2030 (WHO, 2013). The American 
Cancer Society (ACS) estimates that approximately 1,660,290 new cancer cases will be 
diagnosed in the US in 2013 and about 580,350 cancer patients will die in the same year (ACS, 
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2013a). Although international cancer organizations and healthcare systems in many countries 
are implementing effective preventative measures to reduce the burden of cancer by controlling 
for risk factors such as; tobacco use, alcohol use, unhealthy diet and physical inactivity, the effort 
has not proven very successful (WHO, 2013). Therefore, radiation and chemotherapy are still the 
main stay of reducing cancer burden. 
1.2 Anticancer Therapies 
Currently, various treatment options are available to treat cancer. However, the preference for a 
specific treatment depends on the type and stage of cancer, patient’s response to a treatment, 
patient’s overall health and preferences and possible side effects of the treatment. Common   
treatment options available for cancer include; chemotherapy, radiation therapy, hormone 
therapy and surgery.  These treatments are often administered in combinations and have proven 
successful to an extent in eradicating cancer cells. Chemotherapy is a systematic treatment, 
which involves in the use of a single drug or a combination of drugs. Unlike radiation and 
surgery, which are local treatments, chemotherapeutic drugs travel throughout the body to 
destroy cancer cells wherever they are (Gullatte and Gaddis, 2004). Over the past few decades, 
scientific advances have resulted in the development of new chemotherapy drugs, which vary 
widely in their chemical composition and are useful in treating specific forms of cancer. 
Currently available chemotherapeutic drugs can be divided into several groups based on their 
chemical structures and modes of action. Different groups of chemotherapeutic drugs include 
(but are not limited to) alkylating agents, platinum-based compounds, anti-metabolites, anti-
tumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, and miscellaneous chemotherapy 
drugs (Freter and Perry, 2008). 
1.3 Mechanism of Action of Chemotherapeutic Drugs 
Watson and Crick revealed the DNA structure in 1953 (Watson and Crick, 1953). Cancer occurs 
due to mutations in DNA causing abnormal growth. Moreover, lack of DNA repair machinery in 
tumor cells due to certain gene mutations (e.g., checkpoint genes) results in the deregulation of 
DNA replication control mechanism, causing further DNA damage. These findings made DNA 
the primary target in developing anticancer drugs as it became very clear that DNA mutation is 
the main cause of tumorigensis (Gurova, 2009). However, advancements in cancer research in 
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the past few decades led to the development of chemotherapeutic drugs that kill cancer cells by 
blocking or inhibiting cell cycle progression without causing DNA damage. 
The majority of anticancer chemotherapeutic drugs used to treat cancer patients are DNA-
damaging agents. Some of the established groups of drugs that target DNA include: 
antimetabolites, alkylation agents and intercalators. Antimetabolites damage DNA by acting on 
nucleotides, alkylating agents such as nitrogen mustard cause direct DNA damage, while 
intercalators such as actinomycins damage DNA by binding to DNA and inhibiting the activity 
of many enzymes that use DNA as substrate (Malina et al., 2005; Trudi et al., 1991). Similarly, 
recently developed anticancer agents such as inhibitors of topoisomerases I and II, mitomycin C 
and platinum compounds as well as γ-irradiation also cause DNA damage to kill cancer cells 
(Finlay et al., 1989; Gurova, 2009). 
Both alkylating agents and platinum-based drugs, such as nitrogen mustard and cisplatin target 
rapidly dividing cells by attacking nucleophilic sites. These drugs attach to the alkyl or alkyl-like 
group onto the guanine base of DNA causing cross-linking, thus damaging DNA and interfering 
with replication and transcription (Freter and Perry, 2008). Antimetabolites such as 5-
fluorouracil (5-FU) and 6-mercaptopurine (6-MP) destroy tumor cells by interferring in DNA 
and RNA metabolism. Drugs 5-FU and 6-MP target rapidly diving cells by inhibiting specific 
enzymatic steps in the DNA synthesis pathway. For example, nucleoside analogues incorporate 
into DNA in the place of nucleotides and act as terminators, inhibiting further DNA synthesis 
(Freter and Perry, 2008). 
Another anti-metabolic agent, dihydrofolatereductase (DHFR) inhibitor, inhibits the DHFR 
enzyme and prevents the reduction of folic acid into tetrahydrofolic acid, thus disrupting the 
synthesis of thymidine, adenine and guanine (Gullatte and Gaddis, 2004). Another class of 
chemotherapy drugs such as anti-tumor antibiotics (also called anthracyclines) interfere with 
enzymes involved in DNA replication (Freter and Perry, 2008). Though these chemotherapeutic 
agents have proven to be effective in reducing cell division and killing malignant cells; treatment 
with these compounds can not only effect normal cell physiology but also cause molecular 
alterations within cancer cells leading to the development of resistance (Gullatte and Gaddis, 
2004). 
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Chemotherapeutic agents that do not cause DNA damage destroy cancer cells by inhibiting cell 
cycle progression and cell proliferation. Certain groups of chemotherapeutic drugs induce 
programmed cell death in cells by inhibiting protein kinases or by overstabilizing microtubules 
within cells. Flavopiridol is one such novel derivative of cyclin-dependent kinase inhibitors 
(CDKIs) that has the ability to induce apoptosis in neoplastic cells by inhibiting the activity of a 
number of protein kinases necessary for cell proloferation in cancer cells (Wang and Ren, 2010). 
Another group of chemotherapeutic agents called taxanes inhibit cell division in cancer cells by 
overstabilizing microtubles thus disrupting mitosis (Zhou, and Giannakakou, 2005). 
1.4 Need for New Therapies 
Although DNA damaging agents have proven successful in treating many cancers, there are a 
number of limitations associated with this approach. Firstly, DNA damaging agents are not the 
best agents to cure cancer because they can cause long-term damage to the bone marrow 
(Gurova, 2009). Secondly, they are limited to use due to their adverse side effects. Thirdly, the 
high genotoxicity associated with DNA-damaging agents increases the risk for secondary 
cancers (Gurova, 2009). In addition, chemotherapeutic agents also have a devastating effect on 
the patients’ immune system and overall health. The undesirable side effects associated with 
chemotherapeutic drugs coupled with drug resistance and lowering immunity are the main cause 
of treatment failure in cancer patients. Similar many targeted therapies available currently exhibit 
considerable side effects though less severe and different from that of chemotherapeutic drugs. 
Thus, there is the need to develop novel therapies that will rely on the combination of different 
inhibitors to prevent the emergence of resistant sub-population. Therefore, researchers are trying 
to develop new anticancer therapies that target both cancer cell-specific pathways and specific 
proteins that are directly involved in the neoplastic process without causing side effects. A 
desirable way to control tumor without damaging DNA, without developing resistant sub 
population and without lowering immunity is through the development of compounds that 
specifically target cancer cells by altering cellular signaling pathways that favor the induction of 
programmed cell death in tumor cells without causing any harm to normal cells. 
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1.5 Targeted Cancer Therapies 
After decades of research, recent advances in science help in a better understanding of the 
complex intracellular processes of cancer cells. Researchers found that cancer cells differ 
significantly from normal cells in terms of metabolic properties. Cancer cells depend on aerobic 
glycolysis for energy production and have abnormal metabolic characteristics such as increased 
rate of fatty acid synthesis and glutamine metabolism (Zhao et al., 2013). Moreover published 
data suggest that increased fatty acid synthesis causes membrane biogenesis of tumor cell lipids 
fostering increased growth and survival (Pandey et al., 2012). Similarly, increased glutamine 
metabolism in tumor cells releases amino-acid precursors as byproducts, which are necessary for 
rapidly proliferating cells (Erickson and Cerione, 2010). Moreover, emerging evidence shows 
that cancer treatments can be improved by targeting cellular metabolism. Increased drug 
resistance in patients receiving chemotherapy coupled with the high failure rates of cancer 
treatments motivated researchers to develop cancer drugs that are targeted to work specifically 
on cancer cells and not normal, healthy cells (Zhao et al., 2013). 
Targeted cancer drugs also referred to as ‘molecularly targeted drugs’ or ‘molecularly targeted 
therapies’ are substances that interfere with specific proteins or molecules that promote tumor 
growth and progression in cancer cells; thereby blocking the growth and metastasis of cancer 
cells (Pandey et al., 2012). Because cancer targeted therapies mainly target molecular changes 
within cells and are capable of inhibiting proteins that are highly expressed in cancer cells when 
compared with normal cells, they are more effective than other therapies such as DNA damaging 
chemotherapy and radiation treatment. In addition, normal cells are less affected in cancer-
targeted therapies and have less serious side effects, compared to chemotherapy drugs and 
radiation. 
Targeted therapies kill cancer cells by interfering with the ability of the cell to divide, grow and 
repair. Targeted therapies primarily involve the use of humanized monoclonal antibodies and 
small molecules that can alter the normal functioning of cells causing them to die (ACS, 2013b; 
NIH, 2013). Some of targeted therapies available today include: 
a) Signal transduction inhibitors: These targeted therapies block specific enzymes and growth 
factor receptors involved in cancer cell proliferation. Signal transduction inhibitors include:  
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Imatinib Mesylate (protein-tyrosine kinase inhibitor), Genefitinib (epidermal growth factor 
receptor tyrosine kinase inhibitor - EGFR-TK), Cetuximab (epidermal growth factor receptor), 
Lapatinib (epidermal growth factor receptor (EGFR) and human epidermal receptor type 2 
(HER2) tyrosine kinase inhibitor (ACS, 2013b; NIH, 2013). 
b) Targeted therapies that modify the function of proteins that regulate gene expression and other 
cellular functions. Ex: Vorinostat (Zolinza®), Romidepsin (Istodax®), Bexarotene (Targretin®), 
Alitretinoin (Panretin®), Tretinoin (Vesanoid®) (NIH, 2013). 
c) Targeted therapies where monoclonal antibodies deliver toxic molecules to cancer cells 
specifically. Ex: Tositumomab and 131I-tositumomab (Bexxar®) (NIH, 2013). 
d) Anti-angiogenesis drugs: These drugs block the growth of blood vessels that supply blood and 
nutrients to tumors. Ex: Bevacizumab (Avastin®), Ziv-aflibercept (Zaltrap®) (NIH, 2013). 
e) Targeted therapies that act by helping the immune system to destroy cancer cells. Ex: 
Rituximab (Rituxan®), Alemtuzumab (Campath®), Ofatumumab (Arzerra®), Ipilimumab 
(Yervoy™) (NIH, 2013). 
In addition, cancer vaccines and gene therapies are also considered as targeted therapies. 
Although targeted therapies have the ability to specifically target cancer cells without causing 
any harm to normal cells they cannot be considered as a replacement for traditional therapies but 
can be used in combination with traditional therapies. Despite the advantages of targeted 
therapies in specifically killing cancer cells without damaging normal cells, they still cause 
considerable side effects (ACS, 2013b; NIH, 2013). 
Basic function of cells such as cell growth, cell division, cell movement, cell responses to 
specific external stimuli and normal apoptotic process are governed by complex communication 
systems through numerous cell signaling pathways (Erickson and Cerione, 2010). As targeted 
cancer therapies mainly focus on proteins that are involved in cell signaling pathways, blocking 
signals that govern basic cellular functions and activities in cancer cells that grow and divide 
uncontrollably will help to stop cancer progression by inducing tumor cell death. In addition, 
cancer targeted drugs can also be used in combination with other cancer treatments such as 
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chemotherapy and radiation therapy. Quinacrine is one such potential compound that targets 
multiple cell signaling pathways and can be used as a potential anticancer agent. 
1.6 Quinacrine as a Therapeutic Agent 
Quinacrine (QC) (also known as atabrine or mepacrine) is a 9AA derivative that has favorable 
pharmacological and toxicological properties and is widely used in medicine. Atabrine was first 
discovered in German laboratories in 1930’s during a research performed on biologically active 
dyes (Ciak et al., 1967). 
Quinacrine is a bright yellow crystalline powder that has a heterocyclic three-ring structure as 
shown in Figure 1. The acridine compound is a derivative of 9AA through the use of a technique 
called hybrid pharmaphore approach (Ciak et al., 1967). The IUPAC name of Quinacrine is “4-
N-(6-chloro-2-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine”. During the Second 
World War Quinacrine was rediscovered as "American Atabrine" in American laboratories 
(Greenwood, 1995). The compound is ‘readily available as Quinacrine dihydrochloride’ 
(Ehsanian et al., 2011). 
Since, historical times, Quinacrine has been mainly used to treat malaria and giardiasis (Gardner 
and Hill, 2001). Quinacrine hydrochloride pellets were used as a possible agent for non-surgical 
female sterilization in the 1960s and early 1970s by Jaime Zipper (Bashir, 1993). 9AAs are well 
known DNA intercalators. Although 9AA and Quinacrine have similar characteristics, the 
former has not been used in medicine. Quinacrine has generally been prescribed as an anti-
inflammatory drug and used to treat lupus erythematosus and sporadic Creutzfeldt-Jakob disease 
(Toubi et al., 2006; Wallace, 1989). Further, Quinacrine had been used as an intrapleural 
sclerosing agent in patients with high rate of recurrence of pleural effusion or pneumothorax, to 
prevent recurrence (Larrieu et al., 1979; Taylor et al., 1977). 
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Figure 1: Structure of Quinacrine 
Also known as: Mepacrine, Atabrine, Erion, Acrinamine, Antimalarina, Haffkinine, Quinactine, 
Acriquine, Akrichin (Figure adapted from NCBI, 2013). 
Molecular Formula: C23H30ClN3O 
Molecular Weight: 399.9568 
IUPAC Name: {4-[(6-chloro-2-methoxyacridin-9-yl)amino]pentyl}diethylamine 
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1.7 Anticancer Properties of Quinacrine 
The anticancer properties of Quinacrine have been well characterized in various tumors. 
Published data suggests that Quinacrine intercalates into DNA bases with high affinity owing to 
the presence of the acridine ring in its structure.  This interaction with DNA leads to selective 
activation and inhibition of specific cellular signaling pathways that can activate cell-suicidal 
programs, resulting in the reduction of tumors (Neznanov et al., 2009; Zipper et al., 1995). 
However, only a few studies established this association. In a study performed to examine the 
effects of Quinacrine in head and neck cancer patients, researchers found that Quinacrine 
restored the sensitivity to cisplatin in squamous cell carcinomas of head and neck with wild-type 
p53 (Friedman et al., 2007). 
A study performed in rats showed that Quinacrine elicits an innate immune response, which 
could be involved in the elimination of experimental glioma in rats (Reyes et al., 2001; Sotelo et 
al., 2000). Moreover, researchers report that Quinacrine killed breast cancer cells through the 
inhibition of topoisomerase activity (Finlay, 1989). In a study performed to investigate the 
anticancer properties of Quinacrine on breast cancer tumors, researchers found that Quinacrine 
decreased the growth of breast cancer cells by inducing apoptosis through the activation of 
proapoptotic proteins Bax, PARP and p53 and by downregulating of antiapoptotic proteins Bcl-
xL and Nuclear Factor-κB (NF-κB) in MCF7 cells (Preet et al., 2012). In addition, 9AA 
compounds or Quinacrine have been shown to strongly activate p53 and inhibit NF-κB in renal 
cell carcinoma tumor cells. In this study Quinacrine destroyed tumor cells by apoptosis without 
causing genotoxicity (Gurova et al., 2005). 
Further studies showed that Quinacrine also acts as a chemosensitizer when combined with other 
chemotherapeutic agents. It is well known that death receptor-5 (DR5) mediates cell death 
induced by TNF-related apoptosis-inducing ligand (TRAIL) in most tumor cells. However, three 
hepatocellular carcinoma cell lines (HepG2, Hep3B and Huh7) are resistant to TRAIL. 
Therefore, there is a necessity to overcome TRAIL resistance for an effective TRAIL-targetting 
therapy in hepatocellular carcinoma patients resistant to a TRAIL therapy. Quinacrine helps in 
overcoming the resistance of hepatocellular carcinoma cells to TRAIL. A study performed to test 
the chemosensitizing effect of Quinacrine showed that 10-20 µM of Quinacrine treatment for 1-2 
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days alone did not effectively kill hepatocellular carcinoma cells including the HepG2, Hep3B, 
and Huh7 cell lines. However, when Quinacrine is given in combination with TRAIL and 
chemotherapeutic agents, hepatocellular cancer cells were killed effectively because Quinacrine 
significantly increased the levels of DR5, a pro-apoptotic death receptor of TRAIL (Wang et al., 
2011). 
1.8 Apoptosis 
There are a number of cellular signals that determine whether a cell will undergo apoptosis 
(Elmore, 2007). However, the cellular pathways that induce the process of apoptosis are often 
disrupted in cancer by mutations, leading to uncontrolled cell proliferation (McDonnel et al., 
1989). There are at least three different types of cell death: apoptosis, autophagy and necrosis.  
Necrosis is caused by external trauma or injury to the cells, while both apoptosis and autophagy 
are processes initiated from within the cell. In multicellular organisms, the number of cells in the 
body is regulated to maintain tissue homeostasis. This process is not only controlled by genes 
regulating the rate of cell division, but also by controlling programmed cell death. Normally, 
apoptosis causes cell death in response to environmental and developmental signals (Wyllie et 
al., 1980). The Fas/CD95 receptor normally controls cell numbers in the immune system by 
eliminating certain cells through apoptosis. However, when this mechanism is disrupted due to 
mutations in cancer-related genes, a cancer may develop.  Morphologically, the process of 
apoptosis includes cell shrinkage, membrane blebbing, and chromatin condensation (Duprez et 
al., 2009). The apoptotic process is triggered by either internal stimuli or external stimuli. Once 
apoptotic pathway signals are activated, a series of events takes place within the cell until the 
process of cell death is completed. The mechanism of apoptosis involves the activation and 
function of a group of proteases known as the caspases. Two types of apoptotic pathways help in 
the activation of caspases: the death receptor or extrinsic and mitochondrial or intrinsic pathways 
(Earnshaw, 1995). 
The intrinsic pathway is activated by various stimuli including radiation, starvation, heat, and 
DNA damage, and acts through the mitochondria, which are controlled by the Bcl-2 family of 
proteins. The anti-apoptotic Bcl-2 family of proteins maintains the integrity of mitochondria in 
homeostatic conditions by preventing the pro-apoptotic Bcl-2 family members such as Bax and 
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Bak from causing mitochondrial damage. However, under stress conditions the Bcl-2-homology 
3 (BH3)-only proteins are activated, counteracting the anti-apoptotic effect of Bcl-2 family 
members, relieving the inhibition of Bax and Bak. This causes the activation of Bax and Bak, 
which translocates from cytoplasm to mitochondria, and increases the mitochondrial membrane 
permeability by opening the mitochondrial membrane pore complex through which Cytochrome 
c is released into the cytosol. Once Cytochrome c enters the cytoplasm it associates with the 
adaptor protein Apaf-1 and several pro-caspase-9 proteins, forming apoptosomes. The activated 
pro-caspase-9 then cleaves and activates the executioner caspases -3, -6 and -7, which initiate the 
execution of apoptosiss. In addition to the caspases -3, -6, and -7, several other pro-apoptotic 
proteins are released from the mitochondria to trigger the cellular suicide mechanism (Riedl and 
Salvesen, 2007). 
The extrinsic pathway is mediated by external stimuli such as cytokines and growth factors, and 
involves the activation of TNFR family receptors such as TNFR, TRAIL and Fas. Activation of 
these receptors induces a variety of cellular responses leading to formation of a death-inducing 
signaling complex (DISC) which, inturn, activates initiator caspases-8 and/or -10 via homotypic 
death domain interactions (Peter and Krammer, 2003; Wilson et al., 2009). This process takes 
place through the formation of two complexes. Complex I is formed at the plasma membrane and 
consists of TNFR1, TNFR-associated death domain (TRADD), TRAF2, RIP1, cIAP1 and cIAP2. 
Complex II includes TRADD, FADD, and caspase-8 and/or -10. Once the death initiator 
caspase-8 and/ -10 are activated, this leads to the activation of downstream executioner caspases 
such as caspase-3 (Green and Reed, 1998). Caspase-3 is a major player in the execution of 
apoptosis as it cleaves other caspases and essential cell proteins such as poly (ADP-ribose) 
polymerase (PARP) and retinoblastoma proteins. In addition, the activation of caspase-8 also 
activates the death receptor-induced cell death program by activating the mitochondrial pathway 
of apoptosis (Martin and Green, 1995; Peter and Krammer, 2003; Wilson et al., 2009). In 
contrast to this pathway, another extrinsic pathway was discovered in experiments using 
treatment with TNF and Smac mimetics. However, this pathway is totally dependent on kinase 
active RIP1 and involves autodegradation of cIAP1 and cIAP2 by Smac mimetics, leading to 
release of RIP1 from the receptor complex to form a caspase-8 activating platform consisting of 
RIP1, FADD, and caspase-8 (Wang et al., 2008). 
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1.9 Ratio of Anti-Apoptotic and Pro-Apoptotic Factors Decides the Fate of a Cell 
Quinacrine can affect cancer cells via a number of different mechanisms, however the most 
exciting and promising property of Quinacrine is its ability to induce apoptosis in cancer cells. 
Studies show that Quinacrine significantly inhibits cell growth and induces cell death. Reed 
(1998) reported that Bcl-2 and Bcl-xL are anti-apoptotic or death suppressers, whereas Bax 
protien is a death promoter (Reed, 1998). Moreover, published data show that the release of pro-
apoptotic Bax resulted in increased permeability of the mitochondrial membrane, leading to the 
release of Cytochrome c triggering the apoptotic pathway. On the contrary, when anti-apoptotic 
Bcl-2 was released, it decreased the permeability of mitochondrial membrane and prevented the 
release of Cytochrome c; thereby preventing apoptosis (Duprez et al., 2009; Hockenbery et al., 
1990; McDonnel et al., 1989). These data suggest that the fate of a cell depends on the ratio 
between anti-apoptotic and pro-apoptotic signals within cells. 
Furthermore, studies have also shown a correlation between the stages of the cell cycle and the 
levels of Bcl-2 expression. Gui et al. (2005) demonstrated that cells in G1 phase had high 
expression of Bcl-2, and were more resistant to the induction of apoptosis as compared to the 
cells in S-phase of the cell cycle where the expression of Bcl-2 proteins is very low, increasing 
the chance of apoptosis (Gui et al., 2005). 
1.10 Pharmaco-dynamics of Quinacrine 
In addition to the pharmacological properties of Quinacrine as an antimalarial drug and as an 
antibiotic, published data suggests that Quinacrine is also a potential anti-cancer agent. The bio-
molecular binding property of Quinacrine with nucleic acids and phospholipids makes it a 
suitable drug for the treatment of anti-viral and anti-bacterial infections (Wallace, 1989). 
Moreover, published data suggests that Quinacrine is also an effective anti-prion drug. Although, 
prions do not have nucleic acids, Quinacrine seemed to be the most promising compound for 
immediate application for the treatment of prion diseases such as Creutzfeldt-Jakob disease and 
kuru in humans (Ghaemmagham et al., 2009). Korth et al. (2001) tested the efficacy of 
Quinacrine on prions in cell culture models and found that Quinacrine induced the clearance of 
the pathogenic and protease-resistant PrPSc isoform (PrPSc)  (Korth et al., 2001). However, 
Quinacrine did not appear to be effective on prion diseases in vivo. Researchers attribute the 
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translational gap in Quinacrine’s effects to the differences in pharmacodynamic and 
pharmacokinetic properties in vitro and in vivo (Ghaemmagham et al., 2009). 
According to a study on the effects of Quinacrine in Escherichia coli, Quinacrine blocks DNA 
synthesis, and inhibits the syntheses of RNA and protein at a concentration of 8 x 10-4 moles per 
liter. But, when the concentration was reduced to 2 x 10-4 moles per liter, the drug only partially 
inhibited the syntheses of protein and DNA, but not at all RNA synthesis. This finding showed 
that Quinacrine acts by inhibiting DNA replication, transcription, and protein synthesis by 
intercalating into DNA and RNA (Ciak et al., 1967; McCarroll et al., 1981; Whitehouse and 
Boström, 1965). A study performed to investigate the tumor-killing effects with gastric cancer 
cells showed that Quinacrine significantly inhibited cancer cell (SGC-7901) proliferation by 
inducing apoptosis. Moreover, the same authors also revealed that Quinacrine acted on shifting 
the ratio of Bax/Bcl-2 in favoring apoptosis by significantly increasing the levels of proapoptotic 
proteins, cytochrome c, Bax, and p53, and by concomitantly decreasing the levels of 
antiapoptotic protein Bcl-2 (Wu et al., 2012). 
1.11 P53 and NF-κB Pathways are often deregulated in Cancer Cells 
The pro-apoptotic p53 and anti-apoptotic NF-κB pathways are two major stress response 
pathways. Under normal conditions, p53 and NF-κB are inactive in the cytoplasm due to binding 
with specific negative regulators. However, under stress conditions, the negatively regulating 
factors dissociate from p53 and NF-κB in the cytoplasm, resulting in the translocation of p53 and 
NF-κB to the nucleus and bind to several DNA sites. Activation of NF-κB promotes cell survival 
and cell growth, while the activation of p53 promotes cell growth inhibition, temporary arrest of 
cell cycle, irreversible arrest (senescence), or apoptosis. In normal cells, p53 and NF-κB 
pathways negatively regulate each other mutually through simultaneous activation and 
inhibition. However, in tumor cells the p53 and the NF-κB pathways are deregulated, resulting in 
the inhibition of p53 pathway and the activation of NF-κB pathway (Gudkov et al., 2011; Lane 
and Levine, 2012). According to Gurova and colleagues, Quinacrine suppresses NF-κB and 
activates p53 signaling, causing apoptosis in cells (Gurova et al., 2005). 
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1.12 Quinacrine Inhibits NF-κB 
Nuclear factor-κB (NF-κB), the major regulator of inflammation consists of a family of 
transcription factors that help cells to acclimatize and respond to environmental changes. The 
NF-κB transcription factors play a crucial role in basic cell responses such as; inflammation, 
immunity, cell proliferation, differentiation, and survival (Zhong et al., 2002). Activation of NF-
κB is a commonly acquired characteristic of tumor cells. The NF-κB dimers are generally 
retained in inactive form in the cytosol by interacting with IkB (Hayden and Ghosh, 2004). 
However, phosphorylation of IkB leads to its degradation, promoting the translocation to the NF-
κB nucleus, where it induces transcription of target genes. The NF-κB pathway is activated by 
many external stimuli and is regulated by IkBa, p105, or A20 which are NF-κB dependent; 
suggesting the involvement of auto-regulatory feedback loop in the NF-κB response (Hayden et 
al., 2006). 
NF-κB-mediated gene transcription is induced during viral or bacterial infection as well as by 
TNF-α and IL-1β pro-inflammatory kinases. Once the NF-κB is activated, it presents itself as 
trans-activator and leads to the increased expression of inhibitors of apoptotic proteins (Hayden 
et al., 2006). However, in the presence of Quinacrine, the phosphorylation of NF-κB is inhibited 
thus making it a trans-repressor. This transcriptionally inactive state of NF-κB binds to the 
histone deacetylase (HDAC1). This complex of NF-κB and HDAC1 bound to DNA negatively 
regulates NF- κB-dependent gene transcription (Magnaghi-Jaulin et al., 1998). Hence, 
Quinacrine converts NF-κB from a transactivator to a trans-repressor. In a study performed to 
understand the potential mechanism of Quinacrine in vivo, Gorbachev et al. (2007) found that 
contact hypersensitivity response to mice skin cells was mainly because of NF-κB (Gorbachev et 
al., 2007). In addition, Gorbachev and colleagues reported that Quinacrine reduced contact 
hypersensitivity response by inhibiting NF-κB activation and as well as the production of 
cytokines (TNFα, IL-1β, and CCL21) by NF-κB. However, the same group could not identify the 
exact mechanism through which Quinacrine inhibited the activation of NF-κB as well as 
cytokine production (Gorbachev et al., 2007). 
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1.13 Quinacrine Activates P53 
Activation of the tumor suppressor protein p53 induces apoptosis in cells via the mitochondrial 
pathway (Ehsanian et al., 2011).  A potential problem is that the upregulation of NF-κB can 
reduce the tumor suppressor activity of p53, resulting in inflammatory responses. Quinacrine can 
induce a strong p53 response and initiates the process of apoptosis in tumor cells as it can 
simultaneously inactivate NF-κB, making it a very promising drug. Quinacrine stabilizes p53 
protein by blocking its ubiquitination without phosphorylation, thereby activating p53-dependent 
apoptosis in tumor cells, which is independent of the DNA damage repair pathway. In addition, 
Quinacrine induces p53-dependent cell death by increasing the release of Bax, which is a key 
cell death inducer in both the intrinsic and extrinsic apoptotic pathways (Wang et al., 2005). 
Gurova et al. (2005) reported that Quinacrine activates p53 pathway in renal carcinoma cancer 
cells without inducing DNA damage (Gurova et al., 2005). 
1.14 Quinacrine Inhibits AKT Signaling Pathway 
The PI3K-PKB/Akt signaling pathway is a key pathway in cell survival and is involved in the 
NF-κB and p53 issignaling pathways. Akt/PKB is a serine/threonine kinase that plays a key role 
in multiple cellular processes and basic cellular functions such as glucose metabolism, cell 
survival and cell growth. Akt sits at the centre of signaling networks that connects many nodes. 
Each of the targets from these nodes ultimately favors the activation of cell survival pathways, 
thus, contributing to tumorigenesis (Feng and Levine, 2010; Hemmings and Restuccia, 2012).  
However in tumor cells, the Akt pathways receive continuous signals that favor growth and 
metabolism, which leads to tumorigensis. In this process Akt phosphorylates the NF-κB subunit 
p65 and MDM2. Phosporylation of these Akt substrates induces translocalization of MDM2 into 
the nucleus, where it can bind to p53 and promote its degradation. Moreover, nuclear MDM2 can 
transport p53 from the nucleus to the cytoplasm, where it suppresses the p53 activity thereby 
inhibiting apoptosis (Fresno Vara et al., 2004). 
Akt is considered as a principal anti-apoptotic signaling protein involved in the suppression of 
p53 in many different cancers including glioblastomas, pancreatic cancer, renal cell carcinoma, 
breast cancer, and gastric carcinoma. When Quinacrine is administered, it inhibits the Akt 
activity and thus promotes apoptosis through the activation of p53 (Fresno Vara et al., 2004). 
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This property of Quinacrine has been demonstrated by Guo et al. (Guo et al., 2009). Guo et al. 
found that 9AA inhibits Akt activity by preventing its phosphorylation at Ser473. In addition, the 
authors showed that the inhibition is because of the reduced activity of mTOR and not by the 
downregulation of the Akt activity per se. From this, it can be inferred that there is a feedback 
loop between AKT and mTOR, and Quinacrine successfully intereferes with this loop (Feng and 
Levine, 2010; Guo et al., 2009). The effect of Quinacrine on Akt pathway was reaffirmed in a 
study performed to understand the role of the arachidonic acid pathway and epidermal growth 
dactor in neurotensin induced prostate cancer. Hassan and Carraway found that Quinacrine 
inhibited neurotensin and, to a lesser extent, EGF-stimulated phosphorylation of AKT (Hassan 
and Carraway, 2006). 
1.15 Quinacrine Disrupts Arachidonic Acid Pathway 
The arachidonic acid pathway promotes the growth of tumor cells in prostate, gastrointestinal, 
lung, esophageal, and breast cancers. Quinacrine has been proven to effectively disrupt the 
arachidonic acid pathway by the inhibition of phospholipase A2 (PLA2). The inhibition of PLA2 
by Quinacrine leads to a wide range of effects. Firstly, Quinacrine binds to membrane 
phospholipids, primarily phosphatidyl-ethanolamine and intercalates into the cell membrane, 
causing inhibition of membrane binding activity of PLA2. Once PLA2 is blocked, it decreases 
production of arachidonic acid, which in turn results in the inhibition of leukotrienes, prostanoids 
and eicosanoids (Abdel-Latif et al., 1983; Ahmed et al., 1992). Thus, Quinacrine reduces the 
progression of tumor cells through cell cycle by blocking the arachidonic acid pathway. 
1.16 Pharmacokinetics of Quinacrine 
Quinacrine can be administered through oral, intralesional or paralesional, intramuscular, rectal, 
intravenous, transcervical, and interstitial routes. Although intravenous administration is believed 
to be most rapid way through which Quinacrine can be delivered, it is typically administered 
through oral route. When orally administered, the drug is proven to be much more effective as it 
is absorbed rapidly through the gastrointestinal tract. Studies show that when the drug is 
administered through the oral route, the plasma levels of Quinacrine significantly increased 
within 2–4 hours after administration, reaching a peak within 8–12 hours (Wallace, 1989). 
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Besides oral and intravenous routes, Quinacrine is also absorbed rapidly after intrapleural, 
intralesional/paralesional, and intrauterinal administration (Laufe et al., 1996). 
Once within the body, 80–90% of the drug is bound to plasma proteins. The highest 
concentrations of Quinacrine are found in the liver, spleen, lungs and adrenal glands, along with 
skin, fingernails and hair. Low concentrations of Quinacrine are found in the brain, heart and 
skeletal muscle. The half-life of Quinacrine is five to fourteen days depending on the dosing 
regimen. Although bile, sweat and saliva release a small amount of Quinacrine, the major route 
of Quinacrine elimination is through the renal system (Goodman and Gilman, 1954). 
1.17 Adverse Effects of Quinacrine 
Although Quinacrine was found to be effective against prostate, gastrointestinal, lung, 
esophageal and breast cancers, it produces potential toxic side effects. The normal dosage of 
Quinacrine in giardia patients is 100 mg/kg, three times a day for over 5 to 7 days in adults and 6 
mg/kg/day in three divided doses over 5 to 7 days for children (Lerman and Walker, 1982).  At a 
dose of 100 mg daily, Quinacrine causes persistent abdominal cramping, diarrhoea, headache, 
dizziness, and other gastrointestinal symptoms such as anorexia and nausea in patients (Lerman 
and Walker, 1982). Quinacrine is also believed to cause other ill effects such as restlessness, 
vertigo, insomnia, nightmares, hyperirritability, psychosis and convulsions at doses ranging 
between 200 to 1,200 mg daily for ten days (Evans et al., 1984). 
In addition, studies also reported that administration of 100 mg of Quinacrine each day for about 
two and a half years during World War II increased the risk for toxic psychosis and aplastic 
anemia. Studies performed on soldiers that took part in World War II showed that the incidence 
of aplastic anemia was as low as 0.003% and incidence of toxic psychosis was 0.4% when they 
were administered 100 mg of Quinacrine daily for about two and a half years (Custer, 1946; 
Gaskill and Fitz-Hugh, 1945). However, to date the use of Quinacrine has not been 
contraindicated since side effects can be largely reduced or prevented by a decrease in the dosage 
of Quinacrine. Alhough Quinacrine has proven to be effective in treating cancer cells; it requires 
a high dosage regimen (cell arrest at doses less than 5 µM and apoptosis at higher doses (10–
20µM) to cure cancer. In addition, high dosages of Quinacrine cause considerable side effects. 
As a consequence, the application of Quinacrine as a novel chemotherapeutic agent is not 
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justifiable and, therefore, requires the need for further research to enhance the efficacy of 
Quinacrine by eliminating its side effects. 
1.18 Quinacrine Derivatives as Anticancer Agents 
In order to enhance the efficacy of Quinacrine as an anticancer drug, novel derivatives were 
developed based on the 9AA scaffold using a hybrid pharmaphore approach in Dr. Lee’s lab at 
the Northeast Cancer Center in Sudbury, Ontario. The functionality of 9AA derivatives was 
studied using both malignant and non-malignant cells. A handful of those derivatives 
preferentially induced cell death in malignant cells over normal cells. Preliminary data from 
Dr.Lee’s laboratory indicated that these new compounds inhibit malignant cell proliferation with 
greater efficacy and also exhibited reduced toxicity towards normal cells as compared to the 
parent compound Quinacrine. One of the derivatives selected for further investigation based on 
its efficacy and low toxicity is VR118. 
1.19 Specific Aims of This Study 
This particular study investigated the novel VR118 Quinacrine derivative as a potential 
anticancer agent. This study has two specific aims, 
A) To study and evaluate the effects of this novel derivative drug on different human cancer cell 
lines. 
B) To identify the mechanism of action of VR118 in vitro. 
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Chapter 2 
2 MATERIALS AND METHODS 
The following section describes the general methods and routine protocols employed in 
performing the experiments, to test the effectiveness of the compound VR118. 
2.1 Cell Lines 
All the cell lines used in the experiments were purchased from ATCC and include: 
i) HeLa S3 (Human Cervical Carcinoma Cells) and MCF7 (breast 
adenocarcinoma, estrogen receptor positive) cell lines. 
ii) MDA-MB231 (estrogen negative, p53-/-, k-ras mutant breast cancer cell 
lines) 
iii) MDA-MB468 (PTEN negative, RB1 negative, SMAD4, p53 mutant, estrogen 
receptor-negative metastasis-derived breast cancer cell line). 
iv) 184B5 (Chang et al., 2006) and MCF10A non-malignant breast cell lines 
(Gratzner et al., 1975). 
2.2 Culture Media and Reagents Used 
The following is a list of media and medium supplements used in the routine culture of the above 
cell lines: 
i) RPM-I 1640 medium 
ii) 10% (v/v) fetal bovine serum (FBS) 
iii) 100 µg/ml streptomycin 
iv) 100 units/ml penicillin 
v) Dulbecco’s modified Eagle’s medium (DMEM) medium 
vi) 100 µg/ml cholera toxin 
vii) 10 µg/ml insulin, 20 µg/ml EGF (epidermal growth factor) 
viii) 0.5 µg/ml hydrocortisone, 10% (v/v) 
ix) 10% equine serum 
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2.3 Maintenance of Cell Lines 
The following culture protocols were used to maintain the cells under laboratory conditions: 
i) HeLa and MDA-MB231 cells were maintained in RPMI 1640 medium 
supplemented with 10% (v/v) fetal bovine serum (FBS), 100 µg/ml 
streptomycin, and 100 units/ml penicillin. 
ii) MCF7 and MDA-MB468 cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% (v/v) FBS, 100 µg/ml 
streptomycin and 100 units/ml penicillin. 
iii) 184B5 and MCF10A cells were grown in DMEM F12 medium supplemented 
with 100 µg/ml cholera toxin, 10 µg/ml insulin, 20 µg/ml epidermal growth 
factor (EGF), 0.5 µg/ml hydrocortisone, 10% (v/v) 10% equine serum, 100 
µg/ml streptomycin and 100 units/ml penicillin. 
2.4 Drug Treatment 
The experimental design involved dividing the cell samples into test and control groups. The 
VR118 compound is dissolved in Dimethyl sulfoxide (DMSO). The cells in the test group are 
treated with VR118 compound dissolved in DMSO, whereas the cells in control group (sham 
treated cells) are only treated with a volume of DMSO equal to the test sample. In experiments 
where varying concentrations of VR118 compound are used, cells in the control group are 
treated with a concentration of DMSO equal to the highest concentration of VR118 compound 
used in that experiment. Another control group included in the experiment is non-treated group, 
which are grown in a complete media and not treated with either VR118 compound, or DMSO, 
unlike the test group and sham treated cells. Similar to the drug treated samples and the sham 
treated samples; the non-treated samples were collected at the same point of time in every 
experiment. Moreover, the positive control groups varied with each experiment. 
2.5 Clonogenic Assay 
Clonogenic assays are cell survival assays that are generally performed to determine the ability 
of a single cell to grow into a large colony that can be visualized with naked eye in semi-solid 
medium. In this experiment, the protocol by Franken et al. (2006) was adopted: 
i) Cells are seeded out in appropriate dilutions and allowed to grow. 
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ii) After 24 h of post plating, cells were collected, counted and predetermined 
numbers of cells (10,000/ml) were plated in T25 flasks with 5 ml medium. 
iii) MCF7 cells in each T25 flask were treated with increasing concentrations of 
VR118 starting from 0.31 µM, and gradually increasing to 1.5 µM, 6.25 µM, 
25 µM and 100 µM, resulting in exposure of the cells to different 
concentrations of the drug for 24 h. 
iv) On completion of the drug exposure for 24 h, the treated cells were washed, 
trypsinized, and re-suspended in 1 ml of medium and later suspended in 0.4% 
agarose kept in a water bath at 37°C. 
v) The medium is mixed thoroughly using a 3cc syringe equipped with a 16-
gauge needle. 
vi) Later 1 ml of sample was dispensed into each well of a six-well plate and set 
aside for 5 min for agar to solidify 
vii) Upon solidification of agarose, 500 µl of medium was added on the top of 
agar, followed by incubation at 37ºC and 5% CO2 (Franken et al. 2006). 
viii) After 12 days of incubation, colonies were counted from 10 random fields of 
each sample (Franken et al. 2006). 
ix) The average number of colonies per field was plotted against the 
concentration of the cytotoxic agent being tested and only those colonies 
containing more than 50 cells/colony were counted as viable colonies. 
x) Clonogenic assay Also was performed without agrose for MDA-MB231, and 
184B5 cells (Preet et al). For this cells were seeded in 10 cm plates  and 
grown for 24 hr 
xi) Then treated with different concentrations of VR118 (0.5–100 µM) for next 
24 hr. 
xii) Thereafter, cells recounted and medium was replaced with fresh medium, and 
plate was returned to the incubator for (10-12) days. 
xiii) After colony formation, medium was removed and plate was whashed, air 
dried and stained with 0.2% crystal violet (made in 25% methanol and stored 
at room temperature). 
xiv) Then, the plates were washed twice with distilled water, and colonies were 
counted. 
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2.6 Sulphorodhamine B (SRB) Assay 
SRB assays were performed to determine the cell density based on the cellular protein and 
nucleic acids content.  The protocol by Vichai and Kritikara (2006) was adopted for SRB assays: 
i) Each of the 96-well plates were incubated for 24 h after plating them with the 
following number of cells: 
 4,000/ml for MCF7 cells and 184B5 cells 
 3,000/ml for HeLa, MDA-MB231 and MDA-MB468 cells 
ii) After 24 h, the growth medium in each plate was replaced with a medium 
containing different concentrations of VR118 compound and incubated for 
additional 48 h. 
iii) After 48 h, cells in each plate were fixed with 50% ice-cold TCA (trichloro 
acetic acid) and incubated at 4ºC for 1 h, followed by repeated washing in 
running water and air drying. 
iv) Cells were then stained with 0.1% (w/v) SRB solution (400 mg of 
Sulphorodhamine B in 100 ml of 1% acetic acid in water) for 30 min at room 
temperature, and were later re-suspended in 200 µl of 10 mM Tris buffer (pH 
10.5). Absorbance was recorded at a wavelength of 530 nm using a plate 
reader (Molecular devices, Spectra max 340 PC) (Vichai and Kritikara, 
2006). 
v) For positive control, mock-treated cells were used; and for negative control, 
50% TCA treated cells were used. 
vi) The IC50 values were calculated using a sigmoidal dose-response curve 
(variable slope) using Graph Pad Prism V 4.02 (Graph Pad Software, Inc.). 
vii) The following formula was used to normalize the data: 
(Where, Tp is mean O.D. of positive control and Tn is mean O.D. of negative 
control) 
(Mean OD sample - Tn) / Tp- Tn 
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2.7     Cell Proliferation 
Cell proliferation assays are generally employed to evaluate the response of a 
cell population to external factors. For cell proliferation experiments, the 
protocol was adopted from Chang et al. (Chang et al., 2006) 
i) Exponentially growing cells were trypsinized, cell numbers were determined, 
and later a fixed number of these cells (30–40% confluence) were plated on a 
10-cm plate and incubated at 37ºC for 24 h. 
ii) After incubation, these cells were treated with either the IC50 range or higher 
concentration (2/4/6/8/10 µM) of VR118. 
iii) Then cells were collected, and pellets were briefly re-suspended in PBS at pH 
7.4 and later counted after treating with 15 µl of 1% Trypan blue (Chang et 
al., 2006). 
iv) Cells were counted using a hemocyrometer under the microscope in 1 x 1mm 
squares of one chamber, and the average number of cells per square was 
determined. 
v) Counting of cells was performed each day for a replica of four days. Only 
those cells, which excluded Trypan blue, were counted and plotted. 
vi) Each sample and numbers of cells counted each day was plotted using a 
GraphPad computer program. 
2.8 Detection of Apoptosis by Acridine Orange/Ethidium Bromide 
To examine the cellular morphology of MDA-MB231 and MCF7 cells with or without treatment 
with DMSO and/or VR118, the following acridine orange staining method was used. 
i) MDA-MB231and MCF7 cells were grown on glass cover slips overnight at 
37ºC to allow for adherence of cells. 
ii) Cells were then exposed to DMSO and/or VR118 for 24 and 48 h. For this 
experiment, cells were also treated with 6 µg/ml of camptothecin as a positive 
control for apoptosis. 
iii) Each sample was then stained with 100 µg/ml acridine orange (Sigma-
Aldrich) for 5 min and then stained with 100 µg/ml of ethidium bromide 
(Sigma-Aldrich) for 5 min. 
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iv) Finally, the cover slips were washed with 1X PBS and were then gently 
placed onto a glass slide and sealed with clear nail polish. Each sample was 
done one at a time for the cells to be fixed. Pictures were taken using a 
confocal microscope as described by Pearce et al. (2001). 
2.9 Analysis of Cell Cycle Distribution 
This approach helps to detect apoptotic cells with a subG1 DNA content and distribution of cells 
in three major phases of the cell cycle (G1 vs S vs G2/M). The following protocol was used to 
analyze the cell cycle distribution: 
i) MCF7, MDA-MB231 and 184B5 cells were trypsinized after exposure to 
various compounds at different time intervals, ranging from 24 h to 72 h. 
Cells were washed twice in 1X PBS and fixed overnight in 75% ice-cold 
ethanol at -20ºC. 
ii) This was followed by centrifugation of cells, which are later re-suspended for 
1 h in propidium iodide (PI) staining solution (1X PBS, 0.3% Nonidet P-40, 
100 µg/ml RNase A, and 100 µg/ml propidium iodide). 
iii) Re-suspended samples were then analyzed by flow cytometry using an Epics 
Elite Flow Cytometer (Beckman Coulter) according to the protocol by 
Gratzner et al. (Gratzner et al., 1975). 
iv) Later ten thousand events were gated to accurately measure PI intensity. PI 
fluoresces at 623 nm when excited and single parameter displays were 
obtained using the flow cytometeric data acquisition software, and then FL3 
fluorescence signals were recorded. 
2.10 TUNEL Assay 
TUNEL (terminal uridine nick-end labeling) assay is one of the most widely used methods to 
detect apoptotic cells that undergo DNA degradation during the late stage of apoptosis. The 
method is based on detecting DNA strand breaks by enzymatically labeling the free 3'-OH 
termini with fluorescent nucleotides using an In Situ Cell Death Detection Assay Kit (Roche, 
CA, USA). This kit provides complete components including positive and negative control cells 
for conveniently detecting DNA fragmentation by fluorescence microscopy. 
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i) Firstly, cells grown on cover slips were fixed with 4% paraformaldehyde 
(PFA) in PBS (pH 7.4) for 10 min at room temperature. 
ii) Immediately, cover slips were washed and permeabilized with 0.1% Triton 
X-100 in 0.1% PBS for 5 min. A solution was then applied to the samples (50 
µl enzyme solution in 450 µl label solution), according to the protocol 
adapted from (Nunez, 2001). 
iii) Lastly, cells were incubated at 370C in a dark humidified atmosphere for 1 h. 
Samples were then analyzed by confocal fluorescence microscopy using the 
wavelength at 450-500 nm (green). 
 
2.11 Protein Extraction and Quantification 
For the purpose of protein extraction and quantification, the following protocol by Santi and Lee  
(2009) was employed: 
i) Cells were plated on 10 cm plates (Sarstedt) and incubated at 37ºC for 24 h 
before exposing them to 2 µM concentration of VR118. 
ii) Post VR118 treatment, exposed cells were collected at different time points (0, 
24, 48, and 72 h). 
iii) Later whole cell extracts were prepared in RIPA buffer (1X PBS, 1% Nonidet 
P-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1 µM PMSF, 
a protease inhibitor cocktail tablet (Roche Diagnostics), 2 µM sodium 
orthovanadate, and 10 µM sodium fluoride. 
iv) After lysing the cells in RIPA buffer and ice for 10 min, the cell lysates were 
cleared by centrifugation (Beckman Coulter, microfuge 22R) at 4ºC for 15 min 
at 14,000 g (Santi and Lee, 2009). 
v) Finally, protein quantification was carried out using a BCA Assay kit (Pierce) 
and samples were read at 562 nm using a Multiscan MCC/340 plate reader. 
The concentration of unknown proteins was analyzed against the standard 
curve using the Graph Pad Prism version 4.03. 
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2.12 SDS-PAGE 
For performing sodium dodecyl sulfate (SDS) - Polyacrylamide gel electrophoresis (PAGE), 
protocols by Laemmli and Towbin were used: 
i) Samples were prepared by adding 5X loading buffer (0.1 M Tris-HCl, 10% 
[w/v] SDS, 40% [v/v] glycerol, 10% bromophenol blue), and heated for 5 min 
to denature. 
ii) 25 µg or 50 µg of protein sample was loaded onto 6–15% polyacrylamide gel, 
and proteins were seperated by electrophoresis in 1X Running buffer (10X 
Running buffer: 0.25 M Trizma base, 1.92 M glycine, 1% SDS). Run apparatus 
at 120 volts for 2-3 h 
iii) Proteins in the gel were then transferred onto a PVDF membrane (GE Health 
Care), which had been immersed in Transfer buffer (48 mM Tris, 39 mM 
glycine, 20% [v/v] methanol, 0.037% [w/v] SDS), using a semidry transfer 
apparatus at 12 volts for 1 h (Laemmli, 1970; Towbin, 1979). 
2.13 Western Blotting 
This is an important technique used in cell and molecular biology to identify specific proteins 
from a complex mixture of proteins extracted from cells. For Western blotting: 
i) The membrane to which electrophoresed proteins were transferred was 
“blocked” for 1 h by incubating it in Blocking buffer (1X TBS with 0.1% 
Tween, 50 mM Tris-HCl, pH 7.4, 150 M NaCl, 0.1 % [v/v] Tween 20 with 5% 
Carnation non-fat skim milk). 
ii) The membrane was washed with TBST before incubating it with primary 
antibodies overnight (diluted in 5% carnation non-fat skim milk, dissolved in 
0.1% TBS solution) at 4ºC. The titer of antibody used varied and was 
according to the manufacturer’s recommended protocol 
iii) After that, the blot was washed three times in 0.1% TBST, and incubated in a 
secondary antibody (diluted in 0.1% TBST with 5% non-fat skim milk) for 1 h 
at room temperature. 
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iv) This was followed by two more washes with 0.1% TBST, and once with 0.1% 
TBS. The target proteins were visualized using ECL kit (Enhanced 
Chemiluminescense, GE Health care). 
2.14 Densitometric Analysis 
Protein band intensity was determined by densitometry using Alphaease Fluorochem (FC) 8900 
version 4.0.1 software, and graphed using Graph Pad Prism V 4.02 (Graph Pad Software Inc). 
GAPDH or tubulin was used as a loading control. Normalization for loading differences was 
achieved by dividing the densitometry values for individual bands, with the densitometry values 
for loading control (or total protein) in the same lane. 
2.15 Statistical Analysis 
For analysis of each treatment group, data was reported as a mean plus or minus the standard 
error of the mean (SEM). IC50 values were calculated using a sigmoidal-dose response curve, 
which was generated by GraphPad Prism V.402. Values are means of two or three independent 
experiments. Statistical analysis One-way ANOVA was used where p < 0.05 was 
considered to be statistically significant. 
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Chapter 3 
3 RESULTS 
3.1 VR118 Inhibits the Proliferation of Malignant Cell Lines 
To determine the anti-proliferative effect and IC50 of VR118 on malignant and non-malignant 
cell lines, the SRB and clonogenic assays were performed. Findings from both the assays 
revealed that VR118 exhibits significant anti-proliferative effect on malignant cells. The SRB 
assay showed significant anti-proliferative activity on many different breast cancer and HeLa cell 
lines. VR118 compound decreased the cell viability and proliferation of MCF7 cells and was 
found to be very effective. The SRB assay showed that IC50 concentrations of VR118 compound 
were 3.1 µM, 6.2 µM, 3.5 µM and 1.5 µM for MCF7, MDA-MB231, HeLa and MDA-MB468 
cell lines, respectively. Table 1 summarizes the IC50 concentrations of VR118 compound on cells 
lines as per SRB assay. 
In addition to the cytotoxicity of VR118 by the SRB assays, data from clonogenic assay also 
showed that VR118 could significantly inhibit colony-forming capacity of malignant cells. The 
experimental results revealed that VR118 compound was very effective on MCF7, MDA-
MB231, MDA-MB468 and HeLa cell lines compared to the controls. Moreover, VR118 showed 
dose-dependent effects on cell growth and colony forming abilities of cancer cells. The data from 
clonogenic assay were consistent with those from the SRB assay. Table 2 summarizes the IC50 
concentrations of VR118 determined by clonogenic assays. 
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Figure 2: The effects of VR118 on MCF7, MDA-MB468, HeLa, MCF10A and 184B5 cells 
as determined by SRB assays 
The SRB assays were performed to determine the ant-proliferating activity of VR118. As stated 
in the Materials and Methods, MDA-MB468, HeLa, MCF10A and 184B5 cells were seeded onto 
96-well cell culture plates and treated with seven different concentrations of VR118 for 48 h. 
The number of cells was plotted against the varying concentrations of VR118 using a GraphPad 
Prism sigmoidal dose response curve. Represented graphs are means of three independent 
experiments. Error bars represent 95% confidence intervals. 
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Table 1: IC50 of VR118 on MCF7 cells based on data from SRB assays 
IC50 represents the concentration of a drug that is required for 50% inhibition of cell growth 
compared to non-treated controls. IC50 values were calculated using the GraphPad Prism 
sigmoidal dose response curve. Each experiment was performed in triplicate and 
each value represents the mean ± SD of three independent experiments.p < 0.05 vs. Non-cancer 
cells. 
 
 
 
 
 
 
 
 
IC50 (µM) for cancer cells IC50 (µM) Non-cancer cells 
Compound MCF7 MDA-MB231 HeLa MDA-MB468 184B5 MCF-10A 
Quinacrine 4.2±0.2 6.0±1.2 6.1±3.1 5.6±0.4 4.0 ± 0.2 5.0 ± 0.1 
VR118 3.1± 3.5 6.2±2.0 3.5±0.3 1.5 ± 1.0 16.4 ± 0.8 18.2 ± 2.5 
IC
50
MC
F7
MD
A-M
B2
31
He
La
MD
A-M
B4
68
18
4B
5
MC
F1
0A
0
5
10
15
20
25
P value < 0.0001
  
32 
 
Figure 3: Surviving fraction of MCF7, MDA-MB468 and HeLa cells determined by their 
ability to form colonies after 12 days. 
Figure 3 shows representative samples of clonogenic assays for different cell lines exposed to the 
concentrations of VR118 in an IC50 range (3.5 µM). Cells were exposed to different 
concentrations of VR118 (0.7, 1.5, 3.5, 6.25, 12.5, 25, 50 and 100 µM), along with a sham-
treated control. The surviving number of colonies was counted after 12 days as described in 
Materials and Methods. 
 
 
 
 
3.1μM
MCF7 HeLaMDA-­‐MB468
N
on
-­‐t
re
at
ed
VR
11
8
3.5µM	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  µM	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  µM
  
33 
 
Figure 4: Dose-response curves of VR118 determined by a clonognic assay 
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Table 2: IC50 of VR118 on MCF7, MDA-MB231, HeLa, and MDA-MB468 cells as obtained 
from clonogenic assay. 
IC50 represents the concentration of a drug that is required for 50% reduction of colony forming 
ability compared to non-treated controls. IC50 values were calculated using the GraphPad Prism 
sigmoidal dose curves (variable slope). Each experiment was performed in triplicate and 
each value represents the mean ± SD of three independent experiments. p < 0.05 vs. Non-cancer 
cells. 
 
 
 IC50(µM) for cancer cells IC50(µM) Non-
cancer cells 
Compound MCF7 MB231 HeLa MB468 184B5 
Quinacrine 5.9±0.2 7.5±1.0 8.1±3.2 6.6±0.3 4.6±0.21 
VR118 4.1± 1.0 6.5±3.0 4.0±0.32 2.5 ± 1.0 10.0 ± 0.70 
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Data from (Table 1 and Table 2), (Fig. 2 and Fig. 3) suggest that VR118 decreases proliferating 
activity of malignant cells. Observations from the cell proliferation assays further demand the 
need to investigate the cytotoxic property of VR118 compound to differentiate between 
malignant and non-malignant cells. 
3.2 VR118 is more Cytotoxic to Malignant Cells than Non-malignant cells 
To examine whether VR118 shows selective toxicity to cancer cells, anti-proliferative activity of 
VR118 on malignant and non-malignant cells was analyzed using a Trypan blue exclusion assay. 
The result showed that VR118 compound is much less toxic to non-malignant (184B5, 
MCF10A) cells. Unlike Quinacrine, which did not differentiate between malignant and non-
malignant cells, VR118 was capable of differentiating between malignant and non-malignant 
cells while killing. In addition, 184B5 cells did not show any changes in their cell cycle 
progression when treated with the same dose as malignant cells. Data revealed that VR118 did 
not increase plasma membrane permeability in non-malignant breast epithelial cells (184B5 and 
MCF10A cell lines), but had increased plasma membrane permeability in malignant breast 
cancer cells (MCF7, MDA-MB231, MDA-MB468 and HeLa cell lines) (Fig. 3 and Fig. 4). 
When 184B5 cells were treated with the IC50 dose of VR118 for malignant cells, they were not 
as greatly affected as cancer cells (Fig. 5). Similar findings were reported in the SRB assays, 
which showed that VR118 is less toxic to non-cancer cell lines (184B5, MCF10A) (Fig. 2,	   p	   <	  0.05).Results from the Trypan blue exclusion assay clearly demonstrates the cancer cell-specific 
targetting nature of VR118. 
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Figure 5: Anti-proliferative activity of VR118 on different cell lines. 
VR118 showed strong anti-proliferative activity on many different breast cancer and HeLa cell 
lines, but not on non-cancer cell lines (184B5, MCF10A). As described in Material and Methods, 
cells on 10 cm plates were grown in medium containing 2–10 µM concentration of VR118. Cells 
were stained with Trypan blue and counted using a hemocytometer to measure viable cell 
numbers. VR118 significantly decreased the viable MCF7 cell numbers after 24 h, whereas 
sham-treated controls exhibited significant proliferation. Moreover, data shows that VR118 is 
cancer cell specific at low concentration, and the non-cancer cell lines were less affected at 2–6 
µM ranges. The data shows representative plots of three replicates. There were no discernable 
differences among the three independent experiments. Trypan blue is used to stain dead cells. 
Live cell count (not uptaking Trypan blue cells). Total cell count including those stained with 
Trypan blue. 
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Figure 6: VR118 did not affect the cell cycle progression in 184B5 non-malignant breast 
cell lines. 
To examine noticeable changes in the cell cycle progression of 184B5 cells in response to 
VR118, 184B5 cells were exposed to various concentrations of VR118 and were later analyzed 
by flow cytometry. The resultant data did not reveal any sign of cell cycle arrest or apoptosis in 
response to 2–6 µM of VR118.  A total of 10,000 events were analyzed by flow cytometry using 
PI (propidium iodide) staining. Results are expressed as the percentage of total cells in each 
phase of the cell cycle. Sub-G1 displays a cell with lower DNA content than an intact cell, which 
indicates that the cells likely died by apoptosis or other mechanisms resulting in cells possessing 
a subG1 level of DNA content. G1 peak corresponds to the 2N content of DNA. G2/M peak 
corresponds to 4N, S phase represents >2N and <4N content of DNA. Plots shown are 
representative of three independent experiments. From this it can be inferred that VR118 
treatment of 184B5 cells does not generate cells of a sub G1 DNA content, nor does the drug 
induce an accumulation of cells at a particular phase in the cell cycle.  This suggests very little 
effect of VR118 on cell progression through the cell cycle. 
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3.3 VR118 Causes Apoptosis in Breast Cancer Cells 
After confirming that VR118 has the property of killing cells in a cancer-specific manner, I 
decided to study the possible mechanism of VR118 in killing cells and inhibiting growth. The 
induction of apoptosis and cell cycle arrest are both anti-proliferative responses, which likely 
contribute to the anti-neoplastic action of Quinacrine derivatives on cancer cells. To evaluate 
whether VR118 can cause apoptosis, three experiments were performed namely: Acridine 
orange/Ethidium bromide staining, Flow cytometry and a TUNEL assay. 
Acridine orange and Ethidium bromide staining experiments were performed to determine if 
MDA-MB231 and MCF7 cells undergo apoptosis when treated with VR118. Acridine orange 
staining helps to determine cell morphology, cell size and refractive properties of cells treated 
with VR118. The rationale behind Acridine orange/Ethidium bromide staining experiment is that 
normal cell membranes are permeable to acridine orange but not to ethidium bromide stain. 
However, when cell membranes lose their structural integrity, they are permeable to ethidium 
bromide. Results from the double staining experiment revealed that malignant cancer cells 
underwent chromation condensation and extensive membrane blebbing which are hall marks of 
apoptosis, while sham-treated cells did not demonstrate any visible damage to the nuclear or cell 
membrane. Data in( Fig.7 and Fig. 8) clearly show that MDA-MB231 and MCF7 cells treated 
with VR118 have lost their structural integrity after 48 h with numerous blebbings. These 
findings are consistent with the Trypan blue assays. This demonstrates that these cells may be at 
a late stage of apoptosis. The presence of many vacuoles (bright yellow spans) suggests that 
these cells may also undergo autophagy (Fig. 7A). 
A decrease in cell proliferation can be a result of either altered cell cycle progression or cell 
death. Therefore, I investigated the effect of this novel compound on cell cycle progression by 
flow cytometry. Flow cytometry results showed that VR118 induces apoptosis in MDA-MB231 
and MCF7 cells as substabntial amounts of cells were observed in a dose and time dependent 
manner (Fig. 9 and Fig. 10). However, MCF7 data showed that number of cells undergoing 
apoptosis was slower (Fig. 10). 
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Data suggest that VR118 induces apoptosis in cancer cells by causing an increase in sub-G1 cell 
population which is suggestive of apoptosis. Microscopy findings revealed that MDA-MB231 
cells treated with VR118 s showed chromatin condensation and nuclear fragmentation clearly 
indicating that they are undergoing apoptosis. MCF7 cells treated with VR118 showed 
morphologic characteristics similar to apoptosis, including cell shrinkage and membrane 
blebbing. Though VR118 induced apoptosis was immediately visible in MDA-MB231 cell lines, 
the process was delayed in MCF7 cell lines. This data clearly demonstrate the apoptosis inducing 
nature of VR118 in malignant cells. 
I further used TUNEL staining to investigate DNA damage caused by VR118. The TUNEL 
assay is based on the fact that TdT enzyme can adda labelled deoxyuridine triphosphate to the 
free end (3’-termini) of damaged DNA. Data from TUNEL assay revealed that over 40% of 
MDA-MB231 treated with 6 µM VR118 underwent apoptosis (Fig. 11). Late stage apoptosis was 
clearly evident in TUNEL assay with significant delay in MCF7 cells compared with MDA-
MB231 cells (Fig. 11 and Fig. 12). VR118 induced apoptosis was immediately visible in MDA-
MB231 cell lines; whereas, the process was significantly delayed in MCF7 cell lines. These 
findings correlate with data obtained from Acridine orange staining (Fig. 8). Together data from 
the Acridine orange/Ethidium bromide staining, flow cytometry and TUNEL assays clearly 
demonstrate that VR118 causes apoptosis in cancer cells. 
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Figure 7: VR118-induced apoptotic cell death was observed by Acridine orange/Ethidium 
bromide staining. 
MDA-MB231 cells grown on cover slips were treated with 6 µM of VR118 for 24 h. Cells were 
incubated with 100 µg/ml acridine orange and 100 µg/ml of ethidium bromide for 5 min. The 
cover slips were then analyzed by confocal microscopy. A) The cells showed chromatin 
condensation and fragmentation, clearly indicating that they are undergoing apoptosis. Extensive 
membrane blebbing was also evident. Magnification is 400X. Representative images from three 
independent experiments are shown. B) 100 cells were counted from randomly selected field. 
Representative graph is the mean from three dependent experiments. 
Cells undergoing apoptosis are more granular than cells that are not. Live cells have a normal 
nucleus (green); early apoptotic cells have (bright green nucleus) shows condensed or 
fragmented chromatin and belbbing membrain; late apoptotic cells display condensed and 
fragmented (red or orange) chromatin. 
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Figure 8: Exposure to the VR118 shows a sign of apoptotic cell death in MCF7 cells. 
MCF7 cells grown on glass cover slips were treated with VR118 for 24 h and followed by 
staining with acridine orange/ethidum bromide. A) MCF7 cells treated with VR118 (4 µm) 
showed morphology characteristics to apoptosis, including cell shrinkage and membrane 
blebbing. MCF7 cells exposed to VR118 for 48 h showed chromatin degradation in the cells, 
compared to non-treated samples. B) 100 cells were counted from randomly selected field. 
Representative graph is the mean of three dependent experiments. 
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Figure 9: Cell cycle analysis of MDA-MB231 cells exposed to VR118. 
Data shown is flow cytometry profiles of MDA-MB231 cells treated with 4 µM or 6 µM or 10 
µM of VR118. Cells were collected at scheduled timepoints, post-exposure to VR118, fixed 
overnight in 75% ethanol, and then stained with PI solution. Exposure to high concentrations of 
VR118 resulted in an increase of sub-G1 cell population indicating that VR118 induces 
apoptosis. The percentage for the cell cycle distributions of cells was estimated by gating for the 
fluorescent intensity corresponding to the amount of DNA in each event. Gates were adjusted 
with respect to non-treated cells. X-axis represents the DNA content stained with PI. Y-axis 
corresponds to the number of cells. The amount results shown are representative of three 
independent experiments. 
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Figure 10: The effects of VR118 and Quinacrine on the MCF7 cell cycle progression. 
Data shown is flow cytometry profiles of MCF7 cells, treated with IC50 concentration of VR118 
and Quinacrine. Cells were harvested for 72 h post-exposure to VR118, fixed overnight in 75% 
ethanol, and then stained with PI solution for the analysis of DNA content. Exposure to VR118 
resulted in the increase of sub-G1 population, indicating that the compound induces apoptosis in 
MCF7 cells. In contrast, Quinacrine did not induce apoptosis but resulted in cell cycle arrest in S 
phase. The percentage shows cell cycle distributions of cells for each plot as estimated by the 
gating for the fluorescent intensity corresponding to the concentration of DNA in each event. 
Gates were adjusted with respect to sham-treated cells. X-axis represents the DNA content 
stained with PI. Y-axis corresponds to the number of cells. Data shown are representative of the 
mean of three independent experiments. 
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Figure 11: Detection of DNA fragmentation in MDA-MB231 treated cells by a TUNEL 
assay. 
A TUNEL assay measures and quantifies apoptosis by labeling and detecting DNA strand breaks 
in individual cells. A TUNEL assay was carried out by an In Situ cell death Detection kit, 
supplied Fluorescien. The first row shows untreated control cells. The second row shows 
recombinant DNase I (3 µ/ml) treated sample used as positive controls. The third row shows 
MDA-MB231 cells treated with VR118 at 6 µM. Both treated cells and control samples were 
analyzed for the induction of apoptosis after 24 h. MDA-MB231 cells treated with VR118 
underwent rapid apoptosis (35%) compared with untreated control cells (2%). A) The images of 
TUNEL positive cells were captured by a confocal microscope (×400). B) 100 cells were 
counted for each sample and triplicate samples were used. 
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Figure 12: Induction of DNA fragmentation in MCF7 cells after 48 h post-treatment with 
VR118 (4 µM). 
MCF7 cells were treated with VR118 as described in Material and Methods. Cells were 
examined with a TUNEL assay kit to determine apoptosis. Apoptotic cells were visualized by 
confocal microscopy. Triplicate samples were used for both treated and untreated control cells. 
Findings from the TUNEL assay revealed a delay in the process of apoptosis in MCF7 cells. A) 
The images of TUNEL positive cells were captured by a confocal microscope (×400). B) 100 
cells were counted for each sample and triplicate samples were used. 
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Molecular Pathways Involved in VR118 Mediated Apoptosis 
To further understand the underlying molecular mechanisms through which VR118 induces 
apoptosis, Western blotting analysis was performed to analyze important molecular markers 
responsible for apoptosis. Findings revealed that apoptosis is dependent on the mitochondria-
dependent signaling pathway. Findings also revealed that the expression levels of pro-apoptotic 
markers such as Bad and Bax increased significantly in cells undergoing apoptosis. Further 
findings also revealed that VR118 releases cytochrome c and activates PARP to induce apoptosis 
in cancer cells. 
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Figure 13: VR118 induced apoptosis by downregulating anti-apoptotic proteins and 
upregulating pro-apoptotic proteins in MDA-MB231 cells. 
Whole cell lysates were prepared after treating MDA-MB231 cells with 6 µM of VR118 for 
24 h, 48 h, and 72 h. The levels and cleavage status of proteins were analyzed by Western 
blotting using antibodies specific to Bcl-2, Bcl-xL, Bad, Bax, cytochrome C and PARP-1. A) 
Expression levels of the anti-apoptotic proteins Bcl-2 and Bcl-xL were significantly decreased. 
However, that of cytochrome C, Bad, and Bax pro-apoptotic proteins increased in a time-
dependent manner. B) PARP-1 plot shows the full-length PARP (116 kDa) and the larger 
fragment (85kDa) of apoptotically cleaved products. GAPDH and β-tublin were used as a 
loading control. Results are representative of two separate experiments. 
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Figure 14: VR118 reduced the level of the anti-apoptotic proteins, and increased pro-
apoptotic proteins in MCF7 cells. 
MCF7 cells (70% confluent) were treated with two different concentrations of VR118 for 24 h. 
Cells were harvested and cell lysate was prepared at 24 or 48 h timepoint. Proteins, separated in 
10% SDS–PAGE, were transferred to a PVDF membrane. The membrane was probed with anti-
Bax, anti-Bcl-2,  anti Bad, and anti-p53  antibodies according to the manufacturer’s protocol. 
The GAPDH served as a control. Data are the representative loading of two different 
experiments. 
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Figure 15: MCF7 cells treated with VR118 released cytochrome c and activated PARP. 
MCF7 cells were treated with IC50 value (4µM) of VR118. Cells were harvested and cell lysate 
was prepared at 24, 48, 72 h timepoint. Proteins, separated in 8% SDS–PAGE, were transferred 
to a PVDF membrane. The membrane was probed with anti-PARP-1, anti-cytochrome c. The 
GAPDH or β-tubulin used as loading control. Data are the representative loading of two different 
experiments. 
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Chapter 4 
4 DISCUSSION 
Given the heterogeneous nature of cancer and the complex processes involved at cellular and 
molecular levels, the need for effective cancer cell specific targeted therapy remains. Moreover, 
targeting cell signaling pathways that can alter cellular functions in cancer cells is an ideal area 
of target for the development of new anticancer drugs. Current research shows that Quinacrine is 
one such drug that has the capability to kill cancer cells by inducing apoptosis through selective 
activation and inhibition of cell signaling pathways. Recent studies showed that 9AA derivatives 
have proven to be effective against renal carcinoma cancer cells and are reported to affect two 
cellular pathways, by selective inhibition and activation of NF-κB and p53 pathways, 
respectively (Gurova et al., 2005). Although Quinacrine has proven to effectively kill cancer 
cells by targeting specific pathways, studies in vitro showed that it lacks the ability to 
differentiate between malignant and non-malignant cells (Table 1) (Custer, 1946; Gaskill and 
Fitz-Hugh, 1945). Given the advantages and disadvantages of Quinacrine, there is a need for 
developing a compound that has low levels of drug toxicity and cancer cell specificity in 
inducing apoptosis. 
Therefore, to develop a potent and cancer-specific drug, Quinacrine was modified by a hybrid 
pharmacophore approach in Dr.Lee’s lab. This study is based on the hypothesis that the 
anticancer properties of VR118 would be better than the lead compound Quinacrine. The present 
study was performed to examine the effectiveness of the compound Quinacrine. I indeed found 
that compound VR118 more selectively targets cancer cells, compared to its parent compound 
Quinacrine. 
In order to justify the cancer cell-specific targeting nature of VR118, I executed a wide range of 
experiments on malignant cancer cells lines (MCF7, MDA-MB231, MDA-MB468, and HeLa) 
and non-malignant cell lines (184B5 and MCF10A), which led me to make a conclusion that 
VR118 is potentially better than Quinacrine as an anti-cancer agent. In this study, I 
systematically investigated the antiproliferative potential of VR118 in malignant cell lines and 
clarified the mechanism of action through which VR118 kills cancer cells. First, I evaluated the 
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anticancer effect of VR118 on malignant cells. I then confirmed the cytotoxic activity of VR118 
and Quinacrine on malignant and non-malignant cells. Further, I examined the possible 
mechanisms involved in cancer cell killing process of VR118 such as p53 level, cytochrome c, 
and Bax/Bcl-2 ratio and studied the proteins involved in the regulation of apoptosis. Based on the 
findings, I came to the conclusion that VR118 induced apoptosis in malignant cells by causing 
upregulation of p53, resulting in increase in Bax/Bcl-2 ratio, triggering the release of 
cyctochrome c from the mitochondria favoring apoptosis. VR118 exhibited the following cancer 
cell-specific killing properties: a) Anti-proliferative activity and cytotoxicity in a cancer-specific 
manner; b) the major mode of cell killing is by apoptosis; and c) apoptosis is induced by altering 
the Bcl-2/Bax ratio. 
4.1 VR118 suppresses tumor cell proliferation 
One of the principle characteristics of cancer cells is their ability to proliferate uncontrollably, 
leading to tumorigensis. Although Quinacrine exhibited significant anti-proliferative activity 
against cancer cells, its derivative VR118 exhibited generally higher anti-proliferative activity on 
malignant cells with different genetic backgrounds. In this study, I systematically investigated 
the antiproliferative effect of VR118 on malignant cells and noticed that VR118 significantly 
inhibited the proliferation of cancer cells. This effect of VR118 has been demonstrated by both 
SRB and clonogenic assays. VR118 showed significant anti-proliferative effect on MCF7, 
MDA-MB468 and HeLa cells (Fig. 2 and Fig.3). 
Moreover, Clonognic ssays revealed that VR118 exhibited a dose dependent relationship with 
the rate of colony formation decreasing with an increase in concentration of VR118 (Fig.4). The 
inhibition of many different cell lines with different genetic background suggests that VR118 
affects a common mechanism in malignant cell lines that is required for their growth and 
proliferation. Hence, it can be inferred that VR118 exhibits significant anti-proliferative effect on 
malignant cells in a dose dependent manner and has the potential to be a potent anti-cancer drug. 
4.2 VR118 is More Cytotoxic to Malignant Cells than Non-Malignant cells 
The most important criteria for any compound to qualify as a potent drug is the ability to prevent 
toxic effects or side effects on the normal cells of the body. Although Quinacrine has proven 
  
62 
 
successful to interfere with the ability of cancerous cells to divide and reproduce; it causes 
significant damage to normal healthy cells along with cancer cell lines. My observations from 
the study not only showed that VR118 exhibits significant efficacy in killing cancer cells, but 
also showed that it does not have any noticeable effect on non-cancer cells. One of the negative 
aspects of Quinacrine is its toxic effect on non-cancerous cells. In this analysis non-malignant 
breast cancer cells lines namely 184B5 and MCF10A cell lines underwent stress and toxic effects 
when treated with Quinacrine at concentrations applicable for malignant cell lines. In 
comparison, VR118 clearly indicated that it was non-toxic on non-malignant cell lines such as 
184B5 and MCF10A, at least at lower concentrations (Fig.2, Table.1 p < 0.05 vs. Non-cancer 
cells). 
This showed that VR118 clearly differentiates malignant cells from non-malignant cells in vitro 
and demonstrated significant anti-proliferative activity specific to malignant cell lines with 
different genetic backgrounds. The experiment findings also showed that the antiproliferative 
effect of VR118 is partly influenced by the concentration of the drug and the characteristics of 
the cell lines examined. This definitely qualifies VR118 as a potential anti-cancer therapeutic 
drug; since it meets the basic requirement of an ideal drug that is; non-toxicity to non-cancer 
cells. In addition, flow cytometry results revealed that low concentrations of VR118 had no 
significant effect on cell cycle progression in the non-malignant cell line 184B5, but had 
substantial effect on the cell cycle progression in cancer cells. This cancer specific property of 
VR118 without causing substantial harm to normal cells makes it an ideal drug for cancer 
treatment. Although VR118 demonstrated little effect on cell cycle progression and proliferation 
of normal cells in vitro, the true capability of VR118 to selectively kill cancer cells with no 
cytotoxicity towards normal cells will only come from experiments in animal systems. Testing 
the efficacy and specificacy of VR118 in vivo is important because VR118 could possibly have 
physiological effects in living systems that cannot be adequately assessed using cell lines. 
4.3 VR118 Increases Sub-G1 Cell Population in Cancer Cells 
The control of the cell cycle is a key regulatory mechanism for cell growth and proliferation 
(Goranav et al., 2009). Therefore, targeting the cell cycle is one of the key driving forces behind 
the development of new anticancer drugs. Normal human cells respond to DNA damage by 
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activating cell-cycle checkpoints where cells try to repair DNA by temporarily arresting DNA 
replication or cell division (King and Cidlowski, 1998; Pellegata et al. 1996). Temporary 
arresting of cell cycle progression is important for maintaining the genetic integrity (Thompson, 
1995). In circumstances where the DNA damage is irreversible, cells may undergo apoptosis to 
prevent the development of mutated DNA. Therefore, to understand the mechanism through 
which VR118 induced apoptosis, I performed a series of experiments on breast cancer cells and 
non-malignant cells. 
My experimental findings not only supported the cancer cell specificity of VR118, but also 
clarified the mechanism of action through which VR118 induces apoptosis in different two 
malignant cell lines. The apoptotic function in normal mammalian cells is generally regulated by 
p53, a tumor suppressor. However, in tumor cells, the p53 is often mutated. When  MCF7 cancer 
cells are treated with VR118, results showed that it induced apoptosis in cancer cells by causing 
upregulation of p53 slightly. On the contrary, anticancer therapies such as chemotherapeutic 
drugs and radiation therapy kill tumor cells by causing cell cycle arrest at the G0/G1, S, or G2/M 
phase often in a p53 independent manner (Chau and Figg 2009; Murray, 2004; Torres and 
Horwitz, 1998). Cell death independent of p53 is not a perfect process because the arrest of cell 
cycle may cause side effects including miss repair of DNA damage. Therefore, chemotherapeutic 
drugs causing cell cycle arrest may result in mutations (Pietenpol and Stewart, 2003). 
Nonetheless, existing evidence suggests that new generation of drugs can induce apoptosis 
through the inhibition of specific cell signaling pathways (Hsu et al., 2005).  Moreover, 
experimental findings revealed that VR118 does not cause arrest of cell cycle progression prior 
to the induction of apoptosis. 
To determine the apoptosis inducing effect of VR118 and Quinacrine, a series of experiments 
studying the cell cycle and apoptosis morphology were performed using Acridine orange/Ehtium 
bromide staining. In the present study, Quinacrine seemed to induce apoptosis in MCF7 cells 
through cell cycle arrest in S phase (Fig. 10). Similar mechanism of action of parent compound 
Quinacrine was reported by Preet et al. (2012) in breast cancer cells (MCF7) and by Wu et al. 
(2012) in gastric cancer cells (SGC-7901), where Quinacrine exhibited cell cycle arrest by 
significantly decreasing the cell populations in G0/G1 and G2/M phases and inducing apoptosis 
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(Preet et al., 2012; Wu et al., 2012). Contrary to these findings, a study by Gurova et al. showed 
that Quinacrine activated the p53 pathway in renal carcinoma cancer cells without inducing 
DNA damage at low concentrations. Moreover, Gurova et al. (2005) reported that Quinacrine 
stabilized the p53 protein by preventing its ubiquination without phosphorylation suggesting 
apoptosis induction by activating p53-dependent signaling pathways in tumor cells (Gurova et 
al., 2005). Although Quinacrine seemed to cause cell cycle arrest in my experiments, further 
analysis is required to study if the mechanism through which Quinacrine induces apoptosis in a 
dose-dependent manner in malignant cells. 
Unlike Quinacrine, MCF7 cells treated with VR118 showed a sub-G1 peak indicating that the 
compound induces apoptosis in MCF7 cells without causing cell cycle arrest. This shows that 
VR118 may not induce activation of a damage-mediated signaling pathway, unlike its parent 
compound and other chemotherapeutic agents (Gorbachev et al., 2007; Rosenzweig et al., 1997; 
Vainio et al., 1997). Instead, VR118 seems to induce apoptosis through the activation of cell 
signaling pathways. In normal cells, the stability of a genome is maintained, in part, by p53 (also 
known as tumor suppressor). When a normal cell is subject to stress, p53 senses DNA damage 
and determines if the cell should undergo DNA repair by temporarily arresting the cell cycle in 
G1 phase or trigger apoptosis if the damage is irreversible. However, in tumor cells the genetic 
stability can be lost due to defective p53. Once the tumor suppressing function of p53 is lost, it 
leads to loss of the G1 checkpoint where critical DNA repair can be activated to avoid further 
damage by continuous DNA replication (Pellegata et al. 1996). DNA G1 phase is an ideal phase 
for inducing apoptosis by p53 as it increases the expression of pro-apoptotic proteins (Bax) in 
this phase favoring apoptosis (Pellegata et al. 1996). VR118 induced apoptosis in G1 phase 
appears to be independent of cell cycle arrest (Piazza et al., 1997). These findings indicate 
VR118 may be a much safer anticancer drug than Quinacrine. 
Further, the analysis of the FACS data clearly showed that VR118 increased the percentage of 
cells undergoing apoptosis in MDA-MB231 and MCF7 cells in a dose-dependent manner. 
According to the observations made from Acridine/Ehtium bromide staining experiments, the 
activation of apoptosis in MCF7 cells by VR118 is substantially delayed, compared to that in 
MDA-MB231. For example, the substantial amount of sub G(1) peak was visible only after 48-
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96 h in MCF7 cells treated with VR118. Although morphological markers for apoptosis like 
shrinkage and membrane blebbing were evident in MCF7 cells within the first 24 h of post 
exposure to VR118, chromatin degradation was not in pace with that of MDA-MB231 cells. 
Similar findings were observed in the TUNEL assay, where MCF7 cells demonstrated delayed 
DNA fragmentation to at least 48 h post-VR118 (Fig.12). 
The delay in apoptosis in MCF7 cells can be attributable to the fact that MCF7 cells lack caspase 
3, which is an essential component for most apoptotic signaling pathways (Janicke et al., 1998). 
In MCF7 cells, the functional 47-bp inside the exon 3 of the CASP-3 gene, which is very 
important to perform the function of apoptosis, is deleted (Janicke et al., 1998). However, a few 
studies report that the apoptotic process in MCF7 cells is independent of caspase 3, because 
MCF7 cells undergo apoptosis through the formation of apoptotic bodies through biophysical 
alterations. Kawaga et al performed a study to investigate the role of caspase-3 in Bax-induced 
apoptosis using parental MCF7 cells deficient of caspase-3 and cells transfected with the 
caspase-3 gene (MCF7/Casp3). Findings from the study showed parental MCF7 cells deficient of 
caspase-3 failed to undergo morphological nuclear and DNA fragmentation, whereas clones 
transinfected with caspase-3 demonstrated intact nuclear dismantling and DNA fragmentation 
(Kagawa et al., 2001). Researchers of the study also reported that deficiency of caspase-3 did not 
prevent the cells from undergoing Bax-induced apoptosis, but aided in blocking Bax-mediated 
nuclear fragmentation (Kagawa et al., 2001). To further understand the process of apoptosis in 
caspase-3 deficient MCF7 cells, reseachers Liang et al. (2001) treated both mock- and bcl-2-
transfected MCF-7 cells with DNA-cleaving antimitotic agent, neocarzinostatin (NCS). 
Researchers noticed that MCF7 cells underwent apoptosis through release of cytochrome c from 
the mitochondria resulting in decreased levels of Bcl-2 and increased levels of Bax. To further 
understand the process, researchers used caspase inhibitors with overlapping specificities and 
found that MCF7 cells underwent apoptosis through sequential activation of caspases 9, 7 and 6 
(Liang et al., 2001). Similar findings were reported by Janicke et al in 1998 that apoptosis 
inducers such as transforming growth factor-β1, Fas, and TNF or staurosporine activate caspases 
in MCF cells (Janicke et al., 1998). 
Furthermore, in a study performed to examine the anticancer effects of dracorhodin perchlorate 
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(DP), Yu et al. (2013) reported that the treatment of MCF7 cells with DP induced apoptosis 
through translocation of apoptosis inducing factor (AIF) from the mitochondria to the cytoplasm. 
AIF causes the release of cytochrome c from mitochondrion which further activates caspase 3 
inducing apoptosis. However, Yu et al. state that apoptosis in MCF7 cells is independent of 
caspase-3, but dependent on AIF (Yu et al., 2013). Although researchers attribute different 
mechanisms responsible for inducing apoptosis in caspase-3 lacking MCF7 cells, further analysis 
is required to fully understand the mechanism through which VR118 and Quinacrine induce 
apoptosis in MCF7 cells. Moreover, there is scarcity of published data to understand the effect of 
Quinacrine and its derivatives on cell-cycle progression. 
It can be inferred from these observations that VR118 mediated apoptosis is caspase 3 
independent, as MCF7 cells underwent apoptosis. From these observations, it can also be stated 
that VR118 mediated apoptosis in MCF7 cells is p53 dependent. Additionally, it provides 
conclusive evidence that VR118 induces apoptosis without any fascinations for any particular 
stage of the cell cycle. The process of apoptosis therefore deserves much attention due to obvious 
reasons of efficacy of such a drug capable of inducing it. Further, available literature suggests 
that Quinacrine induces apoptosis in breast cancer cells through upregulation of p53. 
4.4 VR118 Activates Apoptosis by Upregulating Pro-apoptotic Signals and 
Downregulating Anti-apoptotic Signals 
Having determined that VR118 can induce apoptosis by specifically targeting cancer cells, I next 
focused on understanding the cellular mechanism through which VR118 induces apoptosis. 
Apoptosis is a major thrust area of anticancer therapy, and experimental findings revealed that 
VR118 is capable of inducing the process. However, understanding the underlying molecular 
mechanisms through which VR118 induces apoptosis is important. To gain insight into the 
molecular mechansim, I examined several proteins involved in the regulation of apoptosis. Data 
from the experiments showed that VR118 causes upregulation of pro-apoptotic protein Bax 
resulting in the release of cytochtome c from the mitochondria. At the same time, VR118 
significantly downregulated anti-apoptotic proteins Bcl-2 and Bcl-xL. PARP protein was also 
cleaved in response to VR118. 
The change in ratio between Bax and Bcl-2 caused by VR118 possibly stimulates the release of 
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cytochrome c from mitochondria into the cytoplasm, similarly to Quinacrine (Duprez et al., 
2009; Hockenbery et al., 1990; Orzáez et al., 2009). The release of cytochrome c from the 
mitochondria can occur either by the death-receptor dependent or extrinsic apoptotic pathway, 
and a death-receptor independent or intrinsic apoptotic pathway (Schuler et al., 2000).  
Cytochtrome c released into the cytosol then interacts with apoptotic protease activating factor 
(APAF-1) in the presence of ATP and leads to the activation of caspase-3, and PARP which is an 
important activator of caspase independent apoptotis (Schuler et al., 2000; Tsann-Long et al., 
1995). These experimental findings further support the key role, p53 plays in VR118 induced 
apoptosis; however,  there may be other mechanisms through which VR118 induces apoptosis. 
4.5 Summary and Conclusions 
In this project, I have investigated the anticancer properties of compound VR118 which is 
derived from Quinacrine using a hybrid pharmacophore approach. In summary, it is clearly 
evident from the experimental findings that the Quinacrine derivative VR118 can be a potent 
anticancer therapeutic drug given its idealistic characteristics such as reduced toxicity on non-
malignant cells; and control on cell proliferation and induction of apoptosis in a substantially 
tumor-specific manner. Given the advantages of VR118 in specifically targeting cancer cells, 
further research and development are warranted. 
4.6 Future Direction 
Although evidence from the experiments clearly indicates that VR118 induces apoptosis in 
cancer cells by acting on the mitochondrial pathway; there appears to be another mechanism 
through which VR118 induces apoptosis in MCF7 cells. Therefore, further studies on caspases 9, 
7 and 6 may need to clarify the VR118-induced apoptotic pathway. Furthermore, examination of 
its efficacy should be verified by in vitro studies. 
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